Related Experiment Video
Updated: Aug 18, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Virus-inhibiting factor in primary and metastatic carcinoma of the liver
Abstract:
Sera from patients with hepatoma, metastatic liver disease, cirrhosis of the liver, and benign diseases of the digestive tract have been tested for a virus-inhibiting factor. Serum samples exerting complete inhibition of virus CPE in a dilution of at least 1:10 per 0.2 ml are considered positive, and those exerting 50% inhibition of CPE are regarded as weakly positive. An apparently positive antiviral activity was noted in the sera of patients with hepatoma (53.3%) and metastatic liver disease (46.6%). Patients with cirrhosis of the liver showed positivity in one of ten sera; no positive antiviral activity could be found in the sera of patients with benign diseases of the digestive tract. The percentage of weakly positive response was 33.3% and 13.3% for hepatoma and metastatic liver disease, respectively, and 10.0% for the benign diseases and 20.0% for the cirrhotic sera. The antiviral activity was more prominent in the embryonic foreskin fibroblasts and to a lesser degree in the bovine epithelial cells NBL-1.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Hepatitis
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release

